Cestrian Capital
Research

SEC-registered independent research, also on the Bloomberg Terminal.
SEC-registered investment adviser. We publish independent, market-neutral equity research and quantitative model portfolios for RIAs, funds and serious investors. Also on the Bloomberg Terminal.
- Products on Plutus
- 1
- On Plutus since
- Jun 2026
The approach
Cestrian Capital Research is an SEC-registered investment adviser. Independent investment research is our only business - we have no other capital markets activities. We cover 86 US-listed stocks and ETFs with live ratings, publish a Daily Market Review every US trading session, and run the SignalFlow suite of quantitative, algorithmic strategies together with model portfolios based on investing styles (eg. income) or sectors (eg. biotech). Our work is independent and market-neutral — no investment banking, no conflicts, nothing to sell but our own analysis. Cestrian research is built for RIAs, funds and serious private investors, and is carried on the Bloomberg Terminal (DS/Cestrian, ASKB/Cestrian) as well as our own website at https://www.cestriancapitalresearch.com/ . The model portfolios we publish here are built by the same team, to the same institutional standard: quantitative, fundamental and technical discipline, transparent and rules-based methodology.
Methodology
Independent and market-neutral — no investment-banking or issuer relationships to bias a view. SEC-registered investment adviser — research produced to a regulated standard. Quantitative at the core — the SignalFlow risk-and-ranking engine drives systematic, rules-based rotation. Fundamental, technical and options-flow analysis on single names, with disciplined risk control. Every rating carries a clear entry, target and stop — no vague calls. Published every US trading day; delivered direct or via the Bloomberg Terminal. Full disclosure of any position held by the firm or its staff.
Credentials
- SEC-regulated RIA
- On The Bloomberg Terminal — DS/Cestrian & ASKB/Cestrian
- Independent & market-neutral
- 86 US-listed names under live coverage
- Daily Market Review, every US session
- SignalFlow quantitative strategies
- Cross-asset algorithimic strategies
The people
Jay Urbain, Ph.D.
Quantitative Research
Mark Bloom
Income Strategy
Alex King
Founder & CEO
Nathan Brinkman
Biotech & Healthcare Strategy
Follow the research
Research meets your portfolio
Explore Cestrian Capital Research
on Plutus.
Explore model portfolios and baskets, and build a strategy around your goals.
Explore Plutus